Latest Breaking News On - Haifa kathrin al ali - Page 1 : comparemela.com

BET inhibitors combined with JAK inhibitors well-tolerated with myelofibrosis

BET inhibitors combined with JAK inhibitors well-tolerated with myelofibrosis
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesMindy valcarcelBydavid statmanJakafi incyteHaifa kathrin al aliBristol myers squibbKrukenberg cancer centerUniversity hospital

BMS-986158–Based Combos May Provide Another Viable Treatment Approach in Myelofibrosis

Haifa Kathrin Al-Ali, MD, provides background on the phase 1/2 study of BMS-986158, presents initial efficacy and safety data from the study, and discusses her hope that novel combination regimens like these could achieve the challenging goal of disease modification in myelofibrosis in the future.

Haifa kathrin al aliUniversity hospital of halle saaleKrukenberg cancer centerTranslational oncologyUniversity hospitalBms 986158Bet inhibitorPhase 1 2 ca011 023 trial nct04817007

Dr Al-Ali on the Safety and Efficacy of BMS-986158 Plus Ruxolitinib or Fedratinib in Myelofibrosis

Haifa Kathrin Al-Ali, MD, discusses the safety and efficacy findings from the dose-escalation portion of the phase 1/2 CA011-023 trial of BMS-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis.

Haifa kathrin al aliUniversity hospital of halle saaleKrukenberg cancer centerTranslational oncologyUniversity hospital

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of. | May 11, 2023

United statesSouth koreaAndrew weiBartl scottJean marie michotLorettaj nastoupilNizarj bahlisMitsuho imaiJohn mascarenhasAmit vermaKevin joseph harringtonDavid paul carboneHemophagocytic lymphohistiocytosisHeinz josef lenzFarrukh awanHusseina tawbi

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant .

United statesSouth koreaAmit vermaSaloman manierAlit taherAndrew weiHemophagocytic lymphohistiocytosisBartl scottJonathan spicerPaul david harker murrayHaifa kathrin al aliJavier munozJavidj moslehiKrina patelFarrukh awanRafat abonour